TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

NEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA. The presentation is scheduled to take place on Monday, January 9, 2023, at 9:45 AM PT.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI™ (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 6

error: Content is protected !!